AstraZeneca has withdrawn the regulatory submissions for the use of Zactima (vandetanib) 100mg in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC), from FDA
Shire has received approval through the European Mutual Recognition Procedure for an extension to the current indication for Fosrenol (lanthanum carbonate). Reportedly, the extension is to make the
Nektar Therapeutics (Nektar) has completed patient enrollment ahead of schedule in its phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is company’s investigational proprietary compound
Eisai and TSD Japan has entered into a license and joint development agreement for the development of denileukin diftitox (generic name) in Japan. Under the terms of the
The National Institutes of Health (NIH) has awarded Excelimmune a Small Business Innovation Research (SBIR) grant to support research aimed at developing new treatments for Clostridium difficile (C.
Regulus Therapeutics (Regulus) has reported that the US Patent and Trademark Office (USPTO) has allowed a patent application within the ‘Esau’ patent family (US Application Serial No 10/909,125).
Novavax has reported that CPL Biologicals, the new joint venture between Cadila in India, has begun construction of a manufacturing facility that will be used to produce pandemic
Zogenix and Desitin Pharmaceuticals (Desitin) have reported that Desitin has filed for European regulatory approval of Sumavel DosePro (sumatriptan injection) needle-free delivery system. Reportedly, the announcement follows successful
Advaxis has received approval from the New England Institutional Review Board (IRB) to enroll the first patient in a phase II clinical trial of cervical dysplasia (cervical intraepithelial
The US District Court, in In re NutriSystem securities litigation, has rejected allegations that top executives of the company had made false and misleading statements about the company’s
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.